The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management

Speciality: Oncology

Description:

A warm welcome to all the medical professionals in this interesting session on understanding the best practices in the treatment of ALK-positive NSCLC.

The CROWN Trial has undeniably marked a pivotal moment in the frontline management of ALK-positive non-small cell lung cancer (NSCLC). This landmark Phase 3 study, comparing the third-generation ALK TKI lorlatinib to crizotinib, has redefined expectations for progression-free survival (PFS) and intracranial efficacy. With an unprecedented median PFS not yet reached even after five years of follow-up for lorlatinib, compared to 9.1 months for crizotinib, the CROWN trial has showcased lorlatinib's remarkable ability to deliver deep and durable responses, particularly in preventing and managing brain metastases, a common and devastating complication in ALK-positive NSCLC. These groundbreaking results establish lorlatinib as a new benchmark, ushering in an era of extended disease control and improved quality of life for patients.

This session, featuring insights from leading experts like Dr. Peush Bajpai, Dr. Ankur Nandan Varshney, and Dr. Vikram Singhal, will delve into the profound implications of the CROWN trial findings for clinical practice. Their expertise will illuminate how these trial results translate into real-world strategies for personalized treatment, dose management, and long-term monitoring. Understanding the safety profile of lorlatinib, including its unique metabolic and CNS-related adverse events, and strategies for their mitigation, remains crucial for optimizing patient outcomes and ensuring sustained benefit from this potent therapy.

Therefore, get an overall knowledge on the understanding of the best practices in the treatment of ALK-positive NSCLC. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.

See More Webinars @ Hidoc Webinars